More than a dozen pharmas have recently struck deals with the White House to lower drug prices. Nevertheless, drugmakers ...

With a pair of Phase III trial flops, Ultragenyx will explore cost reductions as analysts turn attention to an upcoming ...

Corcept sought FDA approval despite finding relacorilant was statistically no better than placebo in one of two Phase III ...

Here, BioSpace looks back at the biggest acquisition deals of 2025. Target: Intra-Cellular Therapies Acquisition date: ...

While Novartis secured the biggest deal of the fourth quarter, a handful of riveting tales emerged from the bottom of the M&A ...

The major depressive disorder failure for BHV-7000 is the drug's second, after Biohaven’s spinocerebellar ataxia treatment ...

Jefferies analysts envision a steady launch curve that could ultimately drive meaningful sales from people who are ...

Despite the definitive failure of Novo Nordisk’s semaglutide in Alzheimer’s, biotech executives, analysts and other industry ...

The biotech, which has a deal with Eli Lilly worth as much as $1.1 billion, is developing two targeted radiopharmaceuticals ...

Policy initiatives have come fast and furious at the FDA this year. While guidances on rare diseases and vaccines have consumed most of the ink, policy shifts aimed at improving FDA efficiencies and ...

AstraZeneca’s investigational ATR kinase inhibitor did not improve overall survival when combined with Imfinzi in patients with non-small cell lung cancer during a Phase III clinical trial, the ...

Analysts called the approval a much-needed win for Novo Nordisk, but warned that the company could struggle to grow sales once rival drugs come to market.